{"product_id":"tesamorelin-5mg","title":"Tesamorelin 5Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eTESAMORELIN — Advanced Growth Hormone \u0026amp; Visceral Fat Research Peptide\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Analogue | Visceral Adipose Tissue | Growth Hormone Regulation | Metabolic Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTesamorelin is a synthetic peptide analogue of Growth Hormone-Releasing Hormone (GHRH), developed to stimulate endogenous growth hormone (GH) secretion and investigate its effects on visceral adipose tissue and metabolic regulation.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOriginally approved by the U.S. Food and Drug Administration (FDA) in 2010, tesamorelin is used in specific prescription formulations to reduce excess abdominal fat in adults living with HIV who have lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy activating growth hormone signaling pathways, tesamorelin influences the physiological processes involved in fat metabolism and endocrine regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts established clinical application is limited to a specific medical population, while other potential metabolic applications remain subjects of scientific investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin acts through the hypothalamic-pituitary growth hormone axis, influencing several important physiological processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Stimulates growth hormone-releasing hormone receptors in the anterior pituitary gland.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndogenous Growth Hormone Secretion:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Promotes the release of naturally produced GH through physiological endocrine signaling pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1 Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased GH secretion stimulates insulin-like growth factor 1 (IGF-1) production, an important mediator of growth hormone activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences metabolic pathways associated with abdominal visceral adipose tissue, contributing to reductions observed in clinical studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Provides a research model for understanding interactions between growth hormone secretion, lipid metabolism, and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Scientific Evidence\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin has been evaluated in controlled human clinical trials involving adults with HIV-associated abdominal lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical research has demonstrated:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat Reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Significant reductions in visceral adipose tissue compared with placebo in the studied population.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAbdominal Fat Distribution:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Measurable improvements in excessive abdominal fat accumulation associated with HIV-related lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone Signaling:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased GH and IGF-1 concentrations consistent with its pharmacological mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research Findings:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of lipid parameters, glucose regulation, and other metabolic outcomes, with results varying across studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant Scientific Distinction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Tesamorelin is not an approved general weight-loss medication. Its demonstrated effect on visceral abdominal fat should not be interpreted as evidence of significant overall body weight reduction or effectiveness for cosmetic fat loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1. Visceral Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of biological pathways involved in the accumulation, regulation, and reduction of visceral abdominal fat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e2. Growth Hormone Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExamination of endogenous GH secretion and its relationship with pituitary endocrine function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e3. IGF-1 Signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch into growth hormone-dependent IGF-1 production and its effects on metabolic physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4. HIV-Associated Lipodystrophy\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical investigation of abnormal fat distribution and excess visceral adipose tissue in adults living with HIV.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e5. Lipid Metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExploration of metabolic pathways associated with fatty acid utilization, triglyceride regulation, and adipose tissue function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e6. Metabolic Health Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of interactions between visceral adiposity, insulin sensitivity, glucose homeostasis, and endocrine signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese areas include both established clinical research and ongoing experimental investigations. They do not represent additional approved therapeutic indications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eRegulatory Status \u0026amp; Clinical Development\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTesamorelin received its initial FDA approval in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFDA-authorized tesamorelin products include prescription formulations marketed under the EGRIFTA brand.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, regulatory approval of a specific pharmaceutical formulation does not extend automatically to independently manufactured or research-grade tesamorelin preparations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin is not approved in the United States for general obesity management, bodybuilding enhancement, or cosmetic weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the European Union, the marketing authorization application for EGRIFTA was withdrawn in 2012. FDA approval should therefore not be interpreted as European marketing authorization.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Potential Adverse Effects\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAlthough tesamorelin has undergone human clinical investigation, its use requires appropriate medical assessment and monitoring.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePotential adverse effects and safety considerations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInjection-Site Reactions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Localized redness, discomfort, or irritation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFluid Retention:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Possible swelling, joint discomfort, or peripheral edema.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eElevated IGF-1 Levels:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased circulating IGF-1 may require clinical monitoring.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose Intolerance:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Potential changes in glucose regulation, including an increased risk of diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHypersensitivity Reactions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Allergic responses may occur.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMalignancy-Related Precautions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Growth hormone and IGF-1 signaling require particular caution in patients with active or previous malignancies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLong-Term Cardiovascular Safety:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Long-term cardiovascular outcomes have not been fully established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Evidence \u0026amp; Limitations\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eImportant scientific limitations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin is not established as a treatment for general obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eReductions in visceral adipose tissue do not necessarily produce significant overall weight loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eImprovements in lipid parameters are not consistent across all studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLong-term cardiovascular benefits have not been demonstrated.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eFat accumulation may return after treatment discontinuation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eResearch-grade preparations cannot be assumed equivalent to FDA-approved pharmaceutical formulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY — WHEN SUPPLIED AS A RESEARCH-GRADE MATERIAL.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch-grade tesamorelin is not intended for human or veterinary administration, personal injection, self-medication, bodybuilding enhancement, or unauthorized therapeutic applications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-use labeling does not constitute pharmaceutical approval or authorization for clinical administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502085013768,"sku":null,"price":140.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660","url":"https:\/\/peptgrind.com\/products\/tesamorelin-5mg","provider":"peptitan","version":"1.0","type":"link"}